drugset / Trial / NCT05687851
Study Of Cadonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer
Phase 2
Recruiting
33 enrolled
Chongqing University Cancer Hospital
Fujian Cancer Hospital · collabHenan Cancer Hospital · collabLiaoning Cancer Hospital & Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
Cadonilimab（AK104）is a humanized IgG1 bispecific antibody that targets PD-1 and CTLA-4. This is a single-arm, multicenter, open-label, phase II study, the purpose of this study is to evaluate the efficacy and safety of Cadonilimab plus radiotherapy in participants with locally advanced cervical cancer who do not tolerate chemotherapy.
Timeline
- Start
- 2022-12-29
- Primary completion
- 2024-12-30
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | Intravenous |